You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Ceritinib is a novel triple negative breast cancer therapeutic agent
|
|---|---|
| Published in |
Molecular Cancer, June 2022
|
| DOI | 10.1186/s12943-022-01601-0 |
| Pubmed ID | |
| Authors |
Shengli Dong, Hassan Yousefi, Isabella Van Savage, Samuel C. Okpechi, Maryl K. Wright, Margarite D. Matossian, Bridgette M. Collins-Burow, Matthew E. Burow, Suresh K. Alahari |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 13% |
| United Kingdom | 1 | 6% |
| France | 1 | 6% |
| India | 1 | 6% |
| Unknown | 11 | 69% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 63% |
| Scientists | 4 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
| Practitioners (doctors, other healthcare professionals) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 12% |
| Student > Doctoral Student | 1 | 6% |
| Student > Ph. D. Student | 1 | 6% |
| Student > Master | 1 | 6% |
| Student > Postgraduate | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 11 | 65% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 12% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Medicine and Dentistry | 1 | 6% |
| Unknown | 12 | 71% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 March 2024.
All research outputs
#1,056,397
of 25,830,005 outputs
Outputs from Molecular Cancer
#52
of 1,960 outputs
Outputs of similar age
#24,480
of 443,982 outputs
Outputs of similar age from Molecular Cancer
#2
of 37 outputs
Altmetric has tracked 25,830,005 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,960 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,982 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.